Evidence map›Paper›PMID 25568994›Full record

ArticleObstetrics and gynecology2015

Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening.

Michelle I Silver, Anne F Rositch, Anne E Burke, Katie Chang, Raphael Viscidi, Patti E Gravitt

Abstract read
In one paragraph

Article in Obstetrics and gynecology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Exploring the role of the oncology nurse in cervical cancer screening programs during times of transition.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michelle I SilverDepartments of Epidemiology, Gynecology and Obstetrics, and Pediatrics and the Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; and the Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Anne F Rositch
Anne E Burke
Katie Chang
Raphael Viscidi
Patti E Gravitt

Funding

HPV Infection Among Perimenopausal Women in the 1945-64 Birth CohorR01CA123467 · NCI · JOHNS HOPKINS UNIVERSITY · PI GRAVITT, PATTI E · 2007 to 2012
$3.1M
When Less is More: Changing Cervical Cancer Screening GuidelinesR36HS022199 · AHRQ · JOHNS HOPKINS UNIVERSITY · PI SILVER, MICHELLE · 2013 to 2013
$38k
AHRQ HHS R36 HS022199NCI NIH HHS R01 CA123467
6 · The paper itself

Abstract

objectiveTo explore attitudes toward new cervical cancer screening options and understand factors associated with those beliefs among women in routine gynecologic care.

methodsWe used an interviewer-administered survey of 551 women aged 36-62 years enrolled in the HPV in Perimenopause Study. Poisson regression with robust error variance was used to estimate prevalence ratios and 95% confidence intervals (CIs) to compare women's preferences for cervical cancer screening methods and frequency.

resultsA majority of women (55.6%, 95% CI 51.4-59.8%) were aware that screening recommendations had changed, yet 74.1% (95% CI 70.3-77.7%) still believed women should be screened annually. If recommended by their doctor, 68.4% (95% CI 64.4-72.2%) were willing to extend screening to every 3 years, but only 25.2% (95% CI 21.9-29.2%) would extend screening to 5 years. Most women (60.7%, 95% CI 56.5-65.7%) expressed a strong preference for Pap testing, and 41.4% (95% CI 37.4-45.6%) expressed at least moderate concern over having a human papillomavirus (HPV) test without a Pap test. A desire for more frequent care, higher degree of worry and perceived risk, and abnormal screening history were all associated with reduced willingness to accept HPV testing and longer screening intervals.

conclusionA majority of routinely screened women indicated a willingness to adopt a cervical cancer screening strategy of cytology alone or Pap-HPV cotesting every 3 years if recommended by their physician. However, they remain concerned about HPV testing and extension of screening intervals to once every 5 years. Our results suggest continued reticence to accepting newer HPV-based screening algorithms among routinely screened women older than age 35 years.

Indexed as

AdultCohort StudiesFemaleHumansMass ScreeningMiddle AgedPapillomavirus InfectionsPatient Acceptance of Health CareTime FactorsUterine Cervical Neoplasms

Identifiers

PMID25568994
PMCPMC4304949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.